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ABSTRACT 
Diffuse large B-cell lymphoma (DLBCL) is one the most common forms of non-
Hodgkin lymphoma and one of the most aggressive B-cell neoplasms. Although most 
patients respond to current standard treatments, a significant number of them relapse 
and become refractory to treatment. Hence, there is a need for new approaches in the 
management of DLBCL. In recent years, a number of studies using next-generation 
sequencing (NGS) have contributed to the characterization of the disease and have 
revealed a set of deregulated cellular mechanisms in DLBCL. However, DLBCL is a 
very heterogeneous disease and additional work is required in order to achieve a 
comprehensive understanding of the mechanisms underlying its lymphomagenesis. 
The work described in this thesis aimed to further characterize the genome of DLBCL 
and identify novel genomic alterations by employing a number of NGS methods. 
Furthermore, this thesis sought to functionally describe the effect of some of these 
alterations and explore how they could be meaningful from a therapeutic perspective. 
We first embarked on a targeted sequencing approach in order to assess the impact of 
mutations in a set of key DNA repair genes. DNA repair is critical in B-cell 
development as it ensures the regulation of antibody diversification processes. The 
results showed that half of the tumors analyzed carry mutations in DNA repair genes 
and the most frequently targeted mechanisms are mismatch repair, DNA damage 
response, homologous recombination and non-homologous end-joining. Moreover, 
functional analysis enabled the association of a number of those mutations to specific 
phenotypes. 
Whole exome sequencing identified a number or previously unreported somatic 
mutation targets in DLBCL. In addition, it revealed that some genes known to be 
involved in DLBCL were mutated at a much higher frequency in Chinese patients as 
compared to patients from Western populations. The impact of mutations in DTX1, a 
gene encoding for a negative regulator of Notch signaling, was functionally assessed 
and a number of mutations were found to be deleterious. 
Finally, whole genome sequencing enabled the identification of structural variations 
such as translocations in the genome of DLBCL. IGH translocations are a hallmark of 
DLBCL and the locus is often found juxtaposed to proto-oncogenes which leads to 
their upregulation. We identified PD-L1, a common culprit of immune suppression in 
cancer, as a novel IGH translocation partner in DLBCL. Translocations involving the 
PD-L1 locus were found to impact patient survival and were associated with the more 
aggressive non-germinal center-like subtype of the disease.  
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1 INTRODUCTION 
 
1.1 DNA REPAIR 
 
1.1.1 DNA and mutagenic factors 
The genome constitutes the genetic heritage and blueprint of an individual. In a 
complex being such as a human, the genomic sequence defining it is the result of a 
lengthy and selective evolutionary process. In order to maintain a well-functioning 
body and assure the perpetuation of the species, the genetic heritage contained within 
the DNA sequence must be guarded and preserved.  
The approximately 3.2*109 base-pairs that form the human genome in each nucleated 
cell are constantly exposed to mutational factors that can alter the DNA sequence. The 
nature of these mutation-inducing factors is variable, as they can be environmental 
such as chemical substances, ionizing radiation and infections, or intrinsic such as 
reactive oxygen species and errors occurring during the replication of DNA. The 
resulting alterations in the DNA can be nucleotide substitutions and DNA single or 
DNA double stand breaks (DSBs), leading to single nucleotide variations (SNVs), 
insertions/deletions (indels) and structural variations (SVs) (1, 2). 
To counteract this, human cells possess a sophisticated machinery composed of an 
array of pathways and effector molecules that are collectively referred to as DNA 
damage response and repair factors. These constantly surveil the genome and ensure 
its repair when it is damaged by mutations or other forms of genetic alterations. 
Depending on their function, they are organized into mechanisms ensuring different 
but complementary and often overlapping tasks (3-5).  
 
1.1.2 DNA damage response 
The DNA damage response (DDR) mechanism is the first line of defense against 
DNA damage and acts as a surveillance mechanism. Upon the detection of lesions in 
the genome, it activates cell-cycle control checkpoints and triggers an appropriate 
DNA repair response (4, 6). This results in cell-cycle arrest, repair of the lesion or 
apoptosis of the cell and therefore ensure that the lesions are repaired; and even more 
importantly that they are not propagated to the next generation of daughter-cells 
(Figure 1) (6, 7). Notable sensor and effector molecules of the DDR pathway are p53, 
CHK1, CHK2, PARP1, DNA-PKcs (PRKDC), ATM and ATR (6, 8).  
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Figure 1: DNA damage response. Intrinsic and extrinsic factors may alter the DNA structure. In 
response to this damage, protective mechanisms are activated that lead to cell cycle arrest, apoptosis 
or repair of the damage. Apoptosis can be induced directly or subsequently to unsuccessful DNA 
repair. 
 
1.1.3 DNA double strand breaks 
Among the most dangerous forms of DNA damage are DSBs. When not properly 
repaired, they cause a cell to undergo apoptosis, a form of programmed cell-death. 
Moreover, unrepaired DSBs can lead to genomic instability (9). DSBs are resolved by 
homologous recombination (HR) or via the non-homologous end-joining (NHEJ) and 
alternative end-joining (A-EJ) pathways (10, 11). ATM, a Ser/Thr kinase plays an 
important role in the repair of DSBs by activating many of the factors involved (12). 
 
1.1.3.1 Homologous recombination 
HR, as the name suggests, uses sequence homology to repair DSB and for this to take 
place a template is required. BRCA1 accumulates at DSB sites and participates in the 
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choice of the HR pathway for the repair of a DSB (13). HR continues with the 
formation of the MRE11, RAD50 and NBS1 (MRN) complex at the site of the break. 
The exonuclease activity of EXO1 ensures the resection of nucleotides situated at the 
break. The resulting exposed single strands are coated by RPA in order to minimize 
damage and prevent the formation of secondary structures. BRCA2 promotes the 
assembly of RAD51/RAD52 to the single strands. RAD51 and RAD52 ensure the 
association of the damaged DNA to the sister chromatid in a process called strand-
invasion. This leads to the formation of characteristic structures known as Holliday 
junctions. The sister chromatid then acts as a template for the extension and repair of 
the damaged strand (Figure 2) (14, 15). 
 
 
Figure 2: Homologous recombination. DSBs 
are detected by the MRN complex and the 
recruitment of BRCA1 to the site of the break 
promotes HR. The exonuclease activity of 
EXO1 results in the exposure of single strands 
that are coated with RPA. Following strand 
invasion, the damaged strands are repaired by 
using the sister chromatid as template. 
 
 
 
 
 
 
 
 
1.1.3.2 Non-homologous end-joining and alternative end-joining 
DSB can also be resolved by the NHEJ pathway. Although it shares a number of 
common molecular factors with HR, the two processes are fundamentally different. 
The NHEJ pathway repairs DNA breaks by joining the two exposed ends without 
making use of sequence homology (16). In the early stages of the process, ATM 
phosphorylates MDC1 and 53BP1 (TP53BP1) (17). This is followed by the 
recruitment of KU70 and KU80 to the site of the break and the formation of 
heterodimers (18). The dimer acts as a scaffold for the recruitment of other molecules 
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to the site (19). DNA-PKcs is believed to initiate the nuclease activity of Artemis 
(DCLRE1C) by phosphorylation, which along with polymerases μ and λ renders the 
ends of the breaks compatible for ligation  (20-22). Finally, XRCC4 and Cernunnos 
promote the ligation of the two ends by DNA ligase IV (Figure 3) (10). A-EJ is the 
second end-joining repair pathway. In contrast with NHEJ, the A-EJ pathway makes 
use of sequence microhomology in order to repair DSBs, although this is not always 
the case (10, 23). In A-EJ, PARP1 associates to the broken DNA ends and not 
KU70/80 (24). A series of molecular factors follows PARP1 to the site, including 
XRCC1, polymerase θ and DNA ligase III (Figure 3) (25, 26).  
 
 
Figure 3: Non-homologous end-joining and alternative end-joining. Repair of DSB by making use 
of the NHEJ and A-EJ pathways. Assembly of the KU70/KU80 to the site leads to the formation of 
the NHEJ protein complex. Recruitment of PARP1 to the site inhibits the formation of the 
KU70/KU80 complex and as a result the DSB is repaired by the A-EJ pathway. 
 
1.1.4 Single nucleotide lesion 
Single nucleotide variations or SNVs in DNA consist of the replacement of one of the 
DNA bases adenine, thymine, guanine or cytosine with one of the other three. A 
single nucleotide alteration, if not correctly repaired, can have detrimental effects as it 
 14 
might lead to the replacement of one amino-acid with another, the introduction of a 
stop codon and thus termination of the extension of the amino-acid chain or altered 
splicing of a transcript. Base-excision repair (BER), nucleotide-excision repair (NER) 
and mismatch repair (MMR) deal with single nucleotide alterations. 
 
1.1.4.1 Base-excision repair 
BER is responsible for removing damaged bases. DNA glycosylases such as UNG 
and OGG1 detect and remove the damaged bases, leaving an abasic DNA backbone at 
the site (27). The APE1 endonuclease cleaves the backbone and introduces a break, 
allowing polymerase β to incorporate the matching nucleotide (28). Finally, the break 
is sealed by DNA ligase III in complex with XRCC1 (Figure 4) (29, 30). 
 
 
Figure 4: Repair of single nucleotide lesions. These three DNA repair pathways assure the repair of 
single nucleotide alterations. BER and NER replace damaged bases and nucleotides. MMR is 
responsible for the correction of replication errors that result in mismatches. 
 
1.1.4.2 Nucleotide-excision repair 
NER deals with bulky loops that are often caused by ultraviolet radiation (31). It 
requires the unwinding of the double strand on the site by the RPA/XPA/XPG and 
TGIIH complex and the excision of nucleotides by XPF associated to ERCC1. PCNA, 
polymerases δ and ε complete the repair along with DNA ligases I and III (Figure 4) 
(32).  
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1.1.4.3 Mismatch repair 
MMR handles incorrectly incorporated nucleotides that result from erroneous 
insertions and deletions during DNA replication (33). The MSH2/MSH6 and 
MSH2/MSH3 heterodimers identify mismatches and abnormal loops in the structure 
of the genome. MLH1 associates to the genome in complex with PMS2 which 
introduces single strand breaks at the site. The exonuclease activity of EXO1 removes 
a number of nucleotides situated around the mismatch. Polymerase δ completes the 
repair process with the aid of PCNA and DNA ligase I (Figure 4) (34). 
 
1.2 ADAPTIVE IMMUNITY AND ANTIBODY GENERATION 
The term “immune system” encompasses a set of mechanisms and structures that 
protect the host from invading biological pathogens such as bacteria, viruses, fungi 
and parasites as well as tumors. Immunity is organized into two major systems, the 
innate and adaptive immune systems (35, 36). 
 
1.2.1 Innate immunity 
 Innate immunity comprises a set of physical barriers that protect the body (including 
the skin and mucosa in contact with the external environment), the complement 
system of proteins and specialized cell types such as macrophages, Langerhans cells, 
dendritic cells, neutrophils, eosinophils, basophils, mast cells and natural killer (NK) 
cells. Cells of the innate immunity express surface receptors that recognize common 
structures found on different categories of pathogens. The innate immune system 
confers an immediate protection against disease that is not specific to the particular 
pathogen (35, 37, 38).  
 
1.2.2 Adaptive immunity 
Adaptive immunity, the other major branch of the immune system, is characterized by 
a slower but specific response to individual pathogens. Its principal components are T 
and B-lymphocytes which express receptors that specifically recognize epitopes, 
antigenic determinants of particular pathogens (36, 39). Development of this 
specificity requires time and therefore adaptive immunity arises much later than innate 
immunity during immune response (39). However, once a pathogen has been 
encountered by the adaptive system, an immunological memory is formed that makes 
it possible to mediate a very fast and efficient response during a future encounter with 
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the same pathogen (36). The two immune systems are not independent, and rather are 
strongly interconnected as the innate immunity is involved in antigen presentation and 
the activation of adaptive immunity (40). 
 
1.2.2.1 T-lymphocytes 
T-cells express the antigen-binding T-cell receptor (TCR) on their surface which 
recognizes epitopes mounted on human leucocyte antigen (HLA) molecules (39). The 
HLA class I molecules are expressed by almost every cell type and present to the 
immune system antigenic determinants from the cytoplasm. T-cells are activated upon 
the formation of a synapse between the TCR and an HLA class I molecule presenting 
a matching epitope. CD8+ cytotoxic T-cells are able to recognize HLA class I 
signaling and respond by the secretion of perforin and granzyme B that cause the 
death of the target-cell (41, 42). Another class of T-lymphocytes, the CD4+ helper T-
cells are activated upon interaction with HLA class II molecules that are expressed by 
professional antigen presenting cells (APC). They respond with the secretion of 
cytokines that mediate the immune response by other cells, notably B-cells (41, 43).  
 
1.2.2.2 B-lymphocytes 
B-cells can also express epitope-binding receptors on their surface. The B-cell 
receptor (BCR) however can bind antigens directly and does not require them to be 
presented by HLA molecules. Engagement of the antigen initiates a signaling cascade 
that leads to the proliferation and differentiation into antibody-producing plasma cells 
and memory B-cells (44).  
 
1.2.3 Antibody production in B-cells 
B-cells secrete their epitope-binding receptor in the form of antibodies following 
differentiation into plasma cells. Antibody production is the main function of the B-
cells. Secreted antibodies bind to their corresponding antigen and lead to a direct 
neutralization, opsonization of phagocytic cells or activate an antibody-dependent-
cell-mediated cytotoxicity by NK cells (44-46). The generation of an immense library 
of antibodies specific to each epitope is achieved as a result of the processes of 
antibody diversification (47). This begins early on in B-cell development in the pro-B-
cell stage, before the cells migrate from the bone marrow to the lymph nodes (45).  
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1.2.3.1 V(D)J recombination 
In the pro-B-cell stage, the enzymes RAG1 and RAG2 introduce DSB into the 
immunoglobulin heavy-chain (IGH) locus on Chromosome 14. This initiates a process 
of V(D)J recombination where segments of the variable (V), diversify (D) and joining 
(J) regions of the IGH locus are recombined to assemble the variable region of the 
antibody gene. This recombination is ensured by the resolution of the DSBs by the 
NHEJ pathway. Each V(D)J recombination cycle produces a unique rearranged IGH 
from which a unique and antigen-specific BCR will arise (10, 48-51). Upon 
expression of the mature BCR, B-cells migrate to the peripheral lymphoid organs 
(lymph nodes, tonsils, spleen, Peyer’s patches and mucosa associated lymphoid 
tissue) where they form germinal centers and undergo the final stages of their 
differentiation (Figure 5) (52).  
 
Figure 5: Antibody diversification processes. V(D)J recombination takes place in the bone marrow. 
RAG1/RAG2 introduce DSBs in the IGH locus that are resolved by NHEJ. The intervening DNA is 
discarded in the form of excision circles. CSR and SHM take place in the germinal centers. 
Mismatches resulting from AID activity in the S regions lead to DSBs that are resolved by NHEJ. 
AID-induced lesions in the V regions during SHM are processed by BER and MMR. 
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1.2.3.2 Class-switch recombination and somatic hypermutation 
Recognition of the cognate antigen by the BCR activates B-cells and triggers the final 
stages of their differentiation. Class-switch recombination (CSR) is a process in which 
the gene coding for the constant (C) region the IgM (Cµ) antibody class is replaced by 
a downstream gene coding for another isotype (Cα, Cγ or Cε). Thus, CSR allows the 
cell to produce different classes of antibodies (IgA, IgG, IgE respectively). CSR is 
initiated by the deamination of cytidine residues in the switch (S) regions of the IGH 
locus by the activation-induced cytidine deaminase (AID) (52). The mismatches 
induced by the activity of AID on the S regions lead to DSBs that are repaired by the 
NHEJ pathway (17). Moreover, AID is also acting on the V regions during the process 
of somatic hypermutation (SHM). Mismatches introduced by AID here are resolved 
by the BER and MMR pathways. The purpose of SHM is to give rise to antibodies 
with enhanced affinities for the matching antigen. These processes finalize the 
differentiation into mature, antibody-expressing B-cells (Figure 5) (52).  
Thus, antibody generation and diversification involves the formation of point 
mutations, DSBs and recombinations in the genome. These expose B-cells to 
particular mutagenic processes that need to be highly regulated and surveilled by 
DNA damage response and repair mechanisms.  
  
1.3 CANCER 
Cancers, also known as malignant neoplasms, are above all a “disease of the genome”. 
They arise due to alterations in the sequence and structure of DNA that lead to a loss 
of control of the cell’s proliferative rhythm (1). Such a transformation is not a single 
event but rather a series of sequential mutations over a long period of time that escape 
the surveillance of the cell’s DNA damage response and repair mechanisms (2, 53). 
Its most defining characteristic is the uncontrolled growth of the transformed cell 
population into an invading tumor that disrupts the normal function of the organism 
(54, 55). Tumors achieve an independence in their rate of growth by sustaining a 
constant proliferation signaling, becoming insensitive to apoptosis and growth 
suppressors, and by manipulating immune responses. As the disease progresses, they 
gain invasive capabilities and metastases occur throughout the body with new tumors 
developing in locations in the body that are distant to the initial transformation site. 
Although the malignant cells compose the bulk of the mass, we now know that tumors 
are complex biological entities and their growth is supported by tumor-associated 
stroma, vasculature and other types of non-malignant cells that are found infiltrated 
into the tumor, forming what is referred to as the tumor microenvironment (55).  
  19 
1.3.1 Tumor suppressor genes and proto-oncogenes 
In normal cells, proliferation, cell cycle progression and division are controlled by 
promoting or suppressing factors that form an equilibrium based on endocrine and 
exocrine signaling. From the early stages in the formation of a malignant tumor, this 
equilibrium is shifted towards perpetual growth. Tumor-suppressor genes that limit 
proliferation are inactivated by mutations whilst growth-promoting proto-oncogenes 
acquire activating mutations (56, 57). TP53, often referred to as the guardian of the 
genome, is a tumor suppressor gene with a central role in the maintenance of genome 
integrity and the progression of cell cycle control. It is found to be mutated in 
approximately 50% of all cancers making it the gene most often associated with 
cancer development (58-60). RB1, TP16, BRCA1, BRCA2, CDK1, AKT1 and PTEN 
are other key tumor-suppressors frequently found to harbor inactivating mutations or 
copy number losses in cancers (61-66). Oncogenes however, whose activity promotes 
tumorigenesis, are found to be deregulated by different mechanisms. They are often 
targeted by mutations that lock them into a constitutively activated state of 
transmitting growth signals, or their expression levels are increased by promoter 
demethylation, copy number gains and structural rearrangements (56). RAS, MYC, 
BCL2, BCL6 and WNT are some of the most commonly dysregulated proto-oncogenes 
in cancers (56, 67-70). Together, loss-of-function mutations in tumor-suppressors and 
gain-of-function mutations in proto-oncogenes are the primary factors that confer 
tumors with perpetually sustained growth signaling and resistance to growth 
suppression and apoptosis. 
 
1.3.2 Angiogenesis 
Angiogenesis is one of the most evident contributors to support tumor-growth by the 
microenvironment. Every cell, including those that are cancerous, requires a constant 
supply of nutrients and oxygen. As a tumor grows uncontrollably, cells are 
progressively distancing themselves from capillaries (71). This, however, is being 
counteracted by the production of angiogenic factors such as the vascular endothelial 
growth factor. This stimulates nearby vessels to grow into the tumor and provide 
access to the blood supply. In fact, the hypoxic environment created by the distancing 
of cells from the vessels is one of the main triggers of the angiogenic switch in a 
tumor (72). Simultaneously however, in order to adapt to their environment, tumor 
cells alter their metabolism and shift towards glycolysis even in the presence of 
oxygen. This phenomenon is known as the Warburg effect (73). 
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1.3.3 The immune compartment 
Another key component of the tumor microenvironment that has received wide 
attention in recent years is the immune compartment. An intriguing and unexpected 
observation is that chronic inflammation can foster disease progression by promoting 
angiogenesis, providing growth signals and contributing to metastasis (55, 74).  
Additionally, malignant cells appear to manipulate immunity in order to avoid 
detection and destruction. Cancerous cells acquire numerous mutations that give rise 
to neo-antigens that should, in theory, render them targetable by the immune system. 
In spite of that, tumors evolve to exploit a set of mechanisms that mask them from 
immune-recognition, block the activity of immune factors or induce the apoptosis of 
immune cells (75). These include the loss of expression of HLA molecules and the 
deregulation of immune-checkpoint pathways. 
The CTLA-4/CD28 – B7 and PD-1 – PD-L1 immune-checkpoint pathways have 
received considerable attention recently as targeting these mechanisms demonstrated 
an impressive therapeutic potential in different malignancies. The two pathways work 
in similar ways to regulate the activity of T-cells that infiltrate the tumor 
microenvironment (76). Their precise mechanisms differ however as CTLA-4/CD28 
interactions regulate early immune responses in lymphoid tissues, whereas the PD-1 – 
PD-L1 axis is mostly active in late responses in the peripheral tissues. Moreover, 
while CTLA-4 ligands are expressed by professional APCs, PD-L1 is expressed by 
many cell types as well as tumor cells (77). 
 
1.3.3.1 CTLA-4/CD28 – B7 
CTLA-4 and CD28 are expressed by CD4+ helper T-cell and they compete for binding 
with B7 on the surface of the targeted cell. Binding to CD28 transmits an activation 
signal to T-cells whilst engagement of B7 by CTLA-4 triggers a negative signaling 
cascade that inhibits T-cell activity (78). Therapeutic antibodies targeting CTLA-4 
such as Ipilimumab inhibit the interaction between B7 and CTLA-4 and block 
negative signaling, while indirectly promoting the binding of B7 to CD28. In the 
United States and the European Union, Ipilimumab has received approval as an 
therapy against melanoma and clinical trials assessing its efficacy against other 
cancers are underway (Figure 6) (79-82). 
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Figure 6: Anti-CTLA-4 treatment. Interaction between B7 and CTLA-4 leads to cell-cycle arrest in 
T-cells. CTLA-4 blockade favors the engagement of B7 by CD28 which leads to the proliferation and 
activation of T-cells thus promoting an effective immune response. 
 
1.3.3.2 PD-1 – PD-L1/PD-L2 
PD-L1 and PD-L2 expressed on antigen presenting cells (APC) and tumor cells 
interact with PD-1, their receptor on T-cells, leading to the functional exhaustion of T-
cells and promoting their apoptosis. Under normal conditions, the function of this 
signaling pathway is to moderate the activity of effector cells and prevent excessive 
damage to the surrounding healthy tissue (83-85).  
Different cancers, however, have been found to exploit this mechanism in order to 
shield themselves from immune attack by upregulating PD-L1 expression (86-89). 
Blocking of the interaction between PD-1 and PD-L1 with therapeutic antibodies in 
order to restore immune function has shown very promising results in clinical trials. 
Nivolumab, an anti-PD-1 monoclonal antibody has received approval from the Food 
and Drug Administration (FDA) in the United States for use in the treatment of 
aggressive melanoma and lung cancer (90). Currently, clinical trials indicate that 
patients affected by a wide spectrum of malignancies like renal carcinoma, bladder 
cancer, head and neck cancers, ovarian carcinoma and Hodgkin lymphoma can benefit 
from anti-PD-1 – PD-L1 treatments (91-94). In addition, the therapeutic effect is 
durable and longer-lasting as compared to CTLA-4-targeting treatments and 
toxicological studies show that it is better tolerated with fewer side-effects (Figure 7) 
(95). 
In recent years, interest fueled by the increasing incidence of cancer and 
advancements in technology, notably in next-generation sequencing, has led to a 
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better understanding of the disease. The newly-acquired knowledge of the process of 
malignant transformation has contributed to the development of new therapeutic 
strategies (96, 97).  
 
 
Figure 7: Anti-PD-1 treatment. The interaction of PD-1 and PD-L1 leads to the functional 
exhaustion of T-cells and promotes their apoptosis. Blocking this interaction by anti-PD-1 (or anti-
PD-L1) therapeutic antibodies can lead to a more robust immune response by lifting inhibitory signals 
induced by the PD-1 – PD-L1 interaction.  
 
1.4 B-CELL LYMPHOMAS 
Lymphomas, myelomas and leukemia constitute a group of cancers called 
hematological malignancies. Lymphomas arise from cells of the lymphoid lineage and 
depending on the cell of origin they are classified as T-cell, B-cell or NK cell 
lymphomas (98, 99). The majority of lymphomas originate from B-cells. The genomic 
recombinations and somatic mutations that B-cells undergo during antibody 
diversification are believed to confer them an additional susceptibility for malignant 
transformation (100). Risk factors that have been associated with lymphomas include 
viral infections such as the Epstein-Barr virus (EBV) and the human 
immunodeficiency virus (HIV), immunosuppressive treatments following organ 
transplantation and germline mutations in key genes involved in apoptosis such as 
BCL2L11, BAG5, BCLAF1, and CASP9. (101-105).   
1.4.1 Hodgkin lymphoma 
Hodgkin lymphoma (HL) which represents 12% of lymphoma cases, is a particular 
subtype of B-cell lymphoma that is distinguished by the presence of large, multi-
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nucleated, CD30+ cells of characteristic morphology known as Reed-Sternberg cells 
(106, 107). Management of HL involves chemotherapy that generally yields very 
good results and the vast majority of patients survive their disease (108).  
 
1.4.2 Non-Hodgkin lymphoma 
Other types of B-cell lymphoma are collectively referred to as non-Hodgkin 
lymphomas (NHL). The two most common types of NHL are follicular lymphoma 
(FL) and diffuse large B-cell lymphoma (DLBCL) (109). FL accounts for 25% of 
NHL and is a mature B-cell lymphoma that arises from the germinal centers of the 
lymph nodes (110). It is considered to be an indolent malignancy, as many patients are 
asymptomatic over long periods of time, however, it remains an incurable disease 
(111). A subset of FL cases, about 35%, undergo histologic transformation into a 
high-grade and much more aggressive disease, DLBCL. The causes behind this are 
not yet clearly defined, but loss of the CDKN2A or CDKN2B-cell-cycle control 
kinases, loss of p53, deregulation of MYC expression, BCL6 translocations, as well as 
B2M and CD58 mutations have been implicated in the transformation (110, 112, 113). 
Evidence also suggests a link between aberrant SHM in FL and transformation into 
more aggressive NHL subtypes (114). Patients whose FL undergoes transformation 
have a poor prognosis even with the use of high-dose chemotherapy (115). This 
emphasizes the need for better understanding of the mechanisms of transformation as 
well as the genetics and pathophysiology of FL and DLBCL. 
 
1.5 DIFFUSE LARGE B-CELL LYMPHOMA 
DLBCL is the most frequent type of B-cell lymphoma, representing approximately 
one third of all new NHL diagnoses (99). It has an annual incidence rate of 
approximately 7 per 100 000 individuals in the United States and this has been 
increasing steadily over the past decades (107, 116). In those aged over 65 years, the 
incidence of DLBCL climbs to 68 per 100 000 persons (107). Although a number of 
cases are due to transformation from FL into DLBCL, the majority of diagnoses are 
de novo DLBCLs (117).  
 
1.5.1 Disease subtypes and common genetic lesions 
DLBCL originates from B-cells in germinal centers that undergo clonal expansion 
following cognate antigen recognition (118). The genetic background and clinical 
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manifestations of the disease vary considerably between cases, making DLBCL a very 
heterogeneous disease (119). Expression profiling has been the basis for classifying 
DLBCL cases into two subtypes, the germinal center B-cell-like (GCB) and the 
activated B-cell-like (ABC) subtypes (120). Molecular profiling has contributed to a 
better prediction of disease outcome and risk stratification for patients (121, 122). The 
ABC subtype is characterized by increased aggressiveness and has been associated 
with a less favorable disease outcome (123). GCB DLBCL is considered to be the 
malignant counterpart of germinal center B-cells. It is characterized by activating 
mutations in EZH2, amplifications in the REL proto-oncogene and translocations of 
BCL2 to the IGH locus that lead to its increased expression. ABC DLBCL resembles 
more the post-germinal center activated B-cells where SHM activity has stopped. Its 
distinctive features are BCL6 translocations and mutations in the regulator of 
hematopoietic differentiation PRDM1. Interestingly, BCL6 translocations and loss-of-
function of PRDM1 both block terminal differentiation of B-cells and their occurrence 
is mutually exclusive. Another hallmark of ABC DLBCL is the chronically activated 
BCR signaling and NF-κB pathway. This is often the result of activating mutations in 
CARD11, MYD88 and CD79B or inactivating mutations in TNFAIP3 (A20). BCL2 is 
also frequently upregulated in the ABC subtype, but in contrast to GCB, this is 
achieved not by genomic rearrangements, but by amplifications of the locus (118, 
121, 123-130). 
GCB ABC 
Mutations in gene coding for histone modifiers 
PI3K/Akt/mTOR activation 
MYC translocations 
BCL2 translocations BCL6 translocations 
REL amplifications BCL2 amplifications 
EZH2 mutations PRDM1 mutations 
PTEN loss BCR – NF-κB activation 
Table 1: Oncogenic pathways in DLBCL. 
 
Other common mutation targets in DLBCLs are genes implicated in the immune 
response such as B2M, CD58 and CD70, the antiproliferative factors TP53, BTG1, 
BTG2 and SGK1, the PI3K/Akt/mTOR pathway member PTEN, the histone modifiers 
MLL2, CREBBP and EP300, and the transcription factor MEF2B (131-135). In 
addition to BCL2 and BCL6, somatically acquired translocations involving the IgH 
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locus, MYC, TP63 and CIITA have also been described in DLBCL. In fact, IgH locus 
rearrangements are considered as a hallmark of the disease (136-140). 
 
1.5.2 The role of antibody diversification in DLBCL 
The mutation load of DLBCL is relatively high when compared to other forms of B-
cell malignancies (128). A contributor to that is aberrant targeting of non-
immunoglobulin regions by AID during the germinal center stage of B-cell 
development in which DLBCL arises. A number of proto-oncogenes such as BCL6, 
RHOH, MYC, PAX5 and PIM1 have been identified as targets of illicit AID activity 
(141). Mismatches introduced by AID can also lead to DSB in the genome that can be 
recombined, resulting in oncogenic translocations between proto-oncogenes and the 
IGH locus (141, 142). Interestingly, studies on AID-deficient mouse models found 
that lack of AID prevents translocations between the IGH locus and MYC (143, 144). 
Moreover, in vitro studies show that BCL2 is cleaved by the RAG complex at its 
major breakpoint region which suggests a role of V(D)J recombination in the 
formation of BCL2 rearrangements (145, 146). These findings demonstrate how 
physiological processes specific to B-cells contribute to the formation of B-cell 
lymphomas.  
 
1.5.3 Immune system evasion 
One of the most frequent mutation targets in DLBCL is B2M which is found to be 
affected by genetic alterations in approximately 30% of cases. Additional mechanisms 
that lead to loss of B2M expression might be active in DLBCL, as 60% of cases are 
B2M-deficient (147). As a result, over half of DLBCLs do not express HLA class I on 
their surface which compromises antigen presentation and masks them from CD8+ 
cytotoxic T-cells (147, 148). Moreover, about 20% of DLBCLs carry mutations in 
CD58, a member of the immunoglobulin superfamily which is important for the 
activation of T-cells and NK cells (147, 149, 150). DLBCL derives from B-cells 
which are professional APCs expressing HLA class II. The loss of expression of HLA 
class II molecules has been described in DLBCL and was found to be associated with 
decreased immunosurveillance and poor disease outcome. In many cases this is due to 
the downregulation of CIITA, the master regulator of HLA class II expression, or the 
expression of FOXP1 (151-153). In summary, DLBCLs have several different ways to 
escape surveillance and attack by the immune system. 
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1.5.4 Management of DLBCL and prospective targeted therapies 
More than half of the patients suffering from DLBCL can be cured by currently 
available treatments (154). However, DLBCL is amongst the most aggressive forms 
of lymphoma and relapse after treatment occurs in a significant proportion of patients. 
These patients are refractory to treatment and usually succumb to their disease, which 
underlines the necessity for establishing new therapeutic options (99, 155).  
 
1.5.4.1 CHOP 
The first generation of chemotherapy combinations for DLBCL was introduced in the 
1970’s and was based on anthracycline regimens (156). Since the early 90’s, the 
classical chemotherapeutic treatment for DLBCL has been a combination of 
Cyclophosphamide, Doxorubicin, Vincristine and Prednisone, commonly referred to 
as CHOP. This regimen provides similar results in terms of survival as the previously 
used anthracycline treatments but is better tolerated by patients (157). 
 
1.5.4.2 Anti-CD20 antibodies 
The next milestone in the management of DLBCL came with the supplementation of 
CHOP with Rituximab (R), an anti-CD20 chimeric therapeutic antibody and the first 
immunotherapeutic agent to be used for the management of DLBCL (158, 159). 
Rituximab contributed to a significant increase in the overall survival of patients of all 
ages and R-CHOP has become the gold standard for the treatment of DLBCL (160). 
Etoposide, a topoisomerase inhibitor is effective against primary mediastinal B-cell 
lymphoma and its overall utility as an adjunct to R-CHOP in DLBCL is currently 
being assessed (160, 161).  
 
1.5.4.3 Salvage therapy 
Autologous stem cell transplantation with CD34+ cells and transplantation with 
autologous T-cells expressing anti-CD19 chimeric antigen receptors are used as 
salvage therapies after relapse following chemotherapy. Although complete remission 
and an increase in overall survival are achieved, outcomes can be further improved, 
hence the need for new approaches in the management of DLBCL (162-164). 
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1.5.4.4 New therapeutic approaches 
Rituximab demonstrates an important “evolutionary step” in the way drugs are 
developed and selected. It is a targeted therapy, specifically directed against a 
molecular marker of B-cell lymphoma, the surface antigen CD20 (165). As such, it 
illustrates a shift from traditional chemotherapy towards advanced therapies aiming at 
specific targets on tumor cells. A number of molecules currently under evaluation are 
listed in Table 2. 
 
Drug Molecule class Targeting feature Status (FDA) 
E7438 EZH2 inhibitors EZH2 activating mutations Phase II trial 
ABT-199 BCL2 inhibitors BCL2 overexpression Phase I trial 
Ibrutinib BTK inhibitors 
Constitutively active NF-
κB pathway 
Phase III trial 
Entospletinib SYK inhibitors 
Constitutively active NF-
κB pathway 
Phase II trial 
BKM120 PI3K blockade 
PI3K/Akt/mTOR 
activation 
Phase II trial 
MK2206 Akt inhibitors 
PI3K/Akt/mTOR 
activation 
Phase II trial 
Everolimus mTOR inhibitors 
PI3K/Akt/mTOR 
activation 
Phase II trial 
Veliparib PARP1 inhibitors 
PARP1 in tumors 
with HR defects 
Phase II trial 
SGN-CD70A CD70 blockade CD70 – CD27 signaling Phase I trial 
- CD27 agonists CD70 – CD27 signaling Not investigated 
Pembrolizumab, 
Nivolumab, Pidilizumab 
PD-1 blockade PD-1 – PD-L1/2 signaling Phase II trial 
Atezolizumab PD-L1 blockade PD-1 – PD-L1 signaling Not investigated 
RO4929097 γ-secretase inhibitor Notch signaling Phase I trial 
Table 2: List of targeted therapies for DLBCL. Information derived from www.clinicaltrials.gov.  
 
The histone-lysine N-methyltransferase EZH2 is frequently mutated in DLBCLs of 
the GCB subtype. Mutations altering the Tyr641 residue in the protein’s SET domain 
are identified in approximately 22% of patients (125). Studies in DLBCL cell lines 
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found that these alterations confer a gain-of-function in EZH2 which results in 
increased trimethylation of H3K27 (166). In vitro and in vivo studies have shown that 
as a consequence, the expression of important tumor suppressor genes is silenced and 
thus Tyr641 mutations in EZH2 are important in promoting GCB lymphomagenesis 
(167, 168). EZH2 inhibitors have shown potential in studies as they promote apoptosis 
and cell-cycle arrest both in vivo and in vitro and are currently the subject of clinical 
trials for their effectiveness against lymphoma (169-171). 
As mentioned earlier, BCL2 and BCL6 are often upregulated in DLBCL and inhibitors 
targeting these anti-apoptotic factors are being investigated (160). Although earlier 
studies of BCL2 inhibitors have shown toxicity due to BCL-XL blockade, newly 
developed agents show more promising results with less side effects (172, 173). 
Studies on BCL6 inhibitors have also provided a proof of principle in mouse studies 
where a reduction in the size of the tumors was observed (174, 175). 
Chronically activated BCR signaling leads to the constitutive activation of the NF-κB 
pathway, a major characteristic of ABC DLBCL (176). The NF-κB pathway 
constitutes an important set of molecular factors involved in proliferation, invasion 
and metastasis and its targeting shows therapeutic potential (177). Loss of A20 and 
mutations in CD79A/B, MYD88 and CARD11 are often associated with a 
constitutively active NF-κB in the ABC subtype of DLBCL (178). Targeting of the 
Bruton’s tyrosine kinase (BTK) by Ibrutinib is highly toxic to ABC DLBCL with 
upstream mutations in CD79A/B but not in patients with downstream CARD11 or 
MYD88 mutations alone. This observation demonstrates the principle of targeted 
therapies and how their outcome can be predicted (127, 179). Patients with mutations 
in other members of the BCR/NF-κB pathway upstream of BTK such as SYK and 
LYN could also potentially benefit from Ibrutinib treatment. 
PI3K/Akt/mTOR signaling is important for various processes relevant to cancer 
development such as survival and proliferation and is linked to the BCR/NF-κB 
pathway through SYK and CD79 (180, 181). The use of SYK inhibitors in DLBCL 
requires further investigation, but data suggests that this approach could be promising 
(182). Mutations of the PTEN tumor suppressor gene are one of the hallmarks of GCB 
DLBCL and they constitute another potent mechanism for the constitutive activation 
of the PI3K/Akt/mTOR pathway in DLBCL (183, 184). Additional classes of drugs 
targeting this pathway have been developed and are undergoing clinical investigation 
(185). These include molecules that block PI3K signaling, Akt inhibitors and mTOR 
inhibitors (186-188). 
The targeting of DNA repair pathways, such as HR, has received growing attention in 
recent years. Although not directly a participant in HR, PARP1 associates to single 
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strand breaks during replication and in the absence of its activity the replication fork 
collapses. This however, is managed by HR in normal cells. In tumor cells with HR 
deficiencies, repair of collapsed replication forks is not possible and leads to cell 
death. PARP1 inhibitors could therefore be used in the context of synthetic lethality to 
treat tumors with HR deficiencies. (189, 190). 
CD27 interaction with CD70 constitutes one of the immune-modulatory pathways 
regulating lymphocyte activity. Expression of CD70 by tumor infiltrating 
lymphocytes and subsequent exhaustion of effector T-cells has been observed in NHL 
(191). Moreover, the overexpression of CD70 by malignant cells has been described 
in B-cell lymphomas where it transmits a proliferative signal favoring tumor growth 
(192, 193). Studies with agonist anti-CD27 antibodies on transgenic mice suggest they 
can restore T-cell activity and promote anti-tumor immunity thereby suggesting 
another potential therapeutic avenue (194). 
An immune checkpoint with a great therapeutic potential currently being investigated 
is the PD-1 – PD-L1/PD-L2 pathway. Up to 87% of HL patients with refractory 
disease have shown a response to treatment with Nivolumab, a PD-1 inhibitor, and in 
vitro studies on DLBCL have demonstrated the restoration of activity in infiltrating T-
lymphocytes upon PD-1 blockade (91, 195). Histological evaluation of DLBCL 
patients has shown that a considerable proportion of patients express the PD-1 ligand 
PD-L1 (196). EBV infection accounts for the expression of PD-L1 in a number of 
tumors. However, the mechanisms of PD-L1 expression in DLBCL are not yet fully 
elucidated (197, 198). Nonetheless, expression of PD-L1 by DLBCL further suggests 
that targeting of PD-1 or its ligands could prove beneficial for patients suffering from 
aggressive and refractory DLBCL. 
Such specific approaches to therapy require an understanding of the genetic 
background of the disease (199). Knowledge of the tumorigenic mechanisms 
particular to an individual case will help in predicting the outcome of therapies and 
make more precise choices of regimen for each patient (160, 200). The 
characterization of cancers, which is crucial to this goal, has been greatly empowered 
in recent years by the rapid development of sequencing technologies (201).  
 
1.5.5 Next-generation sequencing of DLBCL 
One of the main driving forces behind the advancements of biomedical research in the 
past 15 years has been the development of next generation sequencing (NGS) 
methods (96). The Sanger method was used during the first wave of large-scale 
sequencing in cancer genomics. This led to important discoveries that identified a 
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number of key genes involved in cancer. However, the method was too costly, slow 
and laborious to be implemented on a larger scale (202-204). NGS brought a rapid 
decline in the price per nucleotide sequenced and unprecedented progress in the speed 
and throughput of massive parallel sequencing (96, 205). A revolution ensued in 
genomics, transcriptomics and epigenetics as tremendous amounts of data could be 
generated at a manageable cost (206).  
NGS methods have been employed to decipher the genome of DLBCL and much of 
the knowledge on the genetics of DLBCL mentioned earlier in this introduction is the 
result these studies (132, 133, 137, 184, 207). These studies have demonstrated the 
great level of heterogeneity characterizing the genetic landscape of DLBCL and 
prompted further investigation. The identification of clinically relevant biomarkers 
can form the basis for the development of new drugs, aid clinicians in choosing the 
appropriate therapies and establishing reliable prognostic models (208-210).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  31 
2 AIM OF THE STUDY 
 
2.1 GENERAL AIM 
The aim of this thesis is to explore the genome of DLBCL by employing a series of 
NGS methods. The data generated is used to identify novel mutation targets and 
structural alterations that contribute to the lymphomagenesis of DLBCL. Furthermore, 
this thesis aimed to functionally characterize the impact of selected NGS findings and 
explore how they could contribute to new approaches in the treatment of DLBCL. 
 
2.2 SPECIFIC AIMS 
Paper I: This project focused on assessing the role of mutations in DNA repair 
genes in the development of lymphomas. Moreover, it sought to investigate their 
relation to the processes of antibody diversification.  
Paper II: Here, a whole exome sequencing (WES) approach was used to 
identify genes targeted by mutations in DLBCL. In addition, it sought to address 
experimentally the impact of mutations in a number of newly discovered 
mutational targets. 
Paper III: This project investigated the role of genetic alterations as 
mechanisms of PD-1-ligand upregulation in DLBCL. Moreover, it aimed to 
describe the distribution of those alterations across the disease subtypes and their 
impact on patient survival.  
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3 MATERIALS AND METHODS 
 
An extensive description of the reagents, patient material and methods used can be 
found in the scientific papers appended to this thesis. Here is an overview of selected 
methods to facilitate the interpretation of the results. 
 
3.1 TARGET ENRICHMENT BY THE SELECTOR TECHNOLOGY 
The Selector method, which preceded the current Agilent HaloPlex method, was used 
for the enrichment of the coding regions of 73 key DNA repair genes in 29 lymphoma 
samples, 22 DLBCL, 5 FL and 2 Burkitt’s lymphomas (BL), all of which had 
matching blood controls (211). The A20 gene was also included and served as an 
internal quality control. The genomic DNA was first fragmented by restriction 
nucleases and probes labeled with biotin were used to pull-down the 1158 exonic 
target regions with streptavidin-coated magnetic beads. The probe design causes a 
circularization of their target region by being complementary to both its extremities. 
Following the pull-down step, the circularized fragments were ligated and enriched by 
amplification with a Phi29 polymerase (211). Of note, each target region was covered 
by more than one probes as to minimize hybridization failure due to single-nucleotide 
polymorphisms (SNPs). 
 
3.2 SOLID SEQUENCING AND DATA ANALYSIS 
The enriched targets were barcoded and a sequencing library was constructed using 
the standard SOLiD method. The barcoded, adaptor-ligated fragments were attached 
to beads and underwent clonal amplification in an emulsion polymerase chain reaction 
(PCR). The beads were then sequenced with the SOLiD “sequencing-by-ligation” 
method that employs fluorescently-labeled di-base probes. In brief, four fluorophores 
are used in the SOLiD method to label the probes and therefore each color represents 
4 of the 16 possible di-nucleotide combinations. A primer is hybridized to the adaptor 
followed by the first fluorescent probe. The probes and primer are being ligated by a 
DNA ligase present in the reaction mix. The fluorescent light is measured and the next 
probe is incorporated and ligated. Following a cycle of 7 reactions, a 35 base pair read 
is generated. The length of individual reads can be extended by additional cycles. The 
strand is removed by denaturation and a new primer is introduced into the mixture, 
offset by one base as compared to the previous one. The probe ligation cycle is 
repeated five times and the target sequence is resolved. 
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SNPmania, an in-house software, was used for the calling of SNVs as well as for 
small indels. Comparing the minor-allele frequency (MAF) between tumor and blood 
control allowed for the determination of the somatic status of alterations. The hg18 
human genome assembly was used as a reference. An in silico prediction of the 
functional impact of mutations was performed with the SIFT and Polyphen-2 
algorithms (212, 213). Comparison of the allelic ratios of heterozygous positions 
between paired tumor and blood controls enabled the detection of allelic imbalances. 
 
3.3 ILLUMINA HISEQ SEQUENCING 
 
3.3.1 Whole-exome sequencing 
DNA extracted from DLBCL tumors and their paired blood controls was processed 
into 150-200 bp-long fragments prior to WES. Adaptors were ligated to both ends and 
the fragments were purified and amplified using a ligation-mediated PCR method. 
The exonic regions were enriched by hybridization to the SureSelect Biotinylated 
RNA library. The enriched libraries were sequenced on an Illumina Hiseq 2000 
sequencer which utilizes a sequencing-by-synthesis method. In brief, the libraries are 
loaded on a flow cell with primers fixed on its surface. The individual fragments of 
the library hybridize to the primers due to sequence complementarity between the 
fragments’ adaptors and the primers. The fragments are amplified by a solid-phase 
bridge amplification step. Following denaturation of the double strands, reversible 
chain-terminator nucleotides labeled with fluorophores are introduced into the 
reaction mix. A polymerase incorporates the first nucleotide to the single strands. 
Each of the four nucleotides is labeled with a different fluorophore and thus the 
incorporated nucleotide can be identified by a camera. Further on, the chain-
terminator nucleotide is modified in order to render further polymerization of the 
chain possible. The cycle is repeated and the individual reads are produced. 
The raw data was processed to remove the adaptor sequences and filter-out low 
quality reads. The sequencing reads were aligned using the Burrows Wheeler Aligner 
(BWA) (214). Varscan was used for the detection of SNVs and GATK for calling of 
indels (215, 216). Predictions on the impact of missense mutations was performed 
with SIFT and Polyphen-2 as mentioned earlier. The Interactive Genomic Viewer 
(IGV) allowed for visual inspection of the mutations (217). 
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3.3.2 Whole-genome sequencing 
DNA from tumors and paired blood controls was fragmented with a Covaris E-210 
ultrasonicator. The shearing process was adjusted to yield fragments of approximately 
500 bp. The fragments were subsequently purified, end-blunted, A-tailed and ligated 
to adaptors prior to amplification by 10 to 12 PCR cycles. The libraries were then 
quantified by quantitative real-time PCR (qPCR) and a bioanalyzer. Whole-genome 
sequencing (WGS) was performed by the Illumina Hiseq 2000 platform as described 
earlier. A number of additional samples were processed by the Illumina Hiseq X10 
platform (218).  
Mutation analysis was performed similarly to the WES and in addition, SegSeq was 
used for detecting copy number changes (219). Moreover, SVs such as translocations 
were detected with the in-house SeekSV software. 
 
3.3.3 RNA sequencing 
RNA was extracted from tumors and fragmented with the NEBNext Magnesium RNA 
Fragmentation Module. The fragmented RNA was ligated to adaptors and hybridized 
to reverse transcription primers before synthesis of cDNA by the SuperScript III 
reverse transcriptase. The obtained cDNA was amplified by PCR and subsequently 
underwent size selection by AMPure beads. Sequencing of the cDNA libraries was 
performed on the Illumina Hiseq 2000 platform (220).  
The expression levels were calculated with the “fragments per kilobase of transcript 
per million mapped read” (FPKM) method and fusion transcripts were detected with 
the SOAPfuse software (221). 
 
3.4 454 GS FLX+ TITANIUM SEQUENCING 
Selected genes were sequenced in extended cohorts using this method. The target 
regions were amplified in microfluidic PCR reactions on a Fluidigm Access array 
using the FastStart High Fidelity PCR system by Roche. The primers used carried 
CS1/CS2 tail adaptors. The DNA templates from different samples were pooled 
together and added to the array along with barcoded sequencing primers containing 
adaptors complementary to the amplification primer tails. The target regions were thus 
enriched and barcoded in order to be able to distinguish the amplicons derived from 
each individual sample. Following the enrichment step, the libraries were analyzed on 
a 2100 Bioanalyzer by Agilent technologies and purified by gel extraction. Finally, 
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sequencing was performed on a GS FLX+ System and the data was analyzed by the 
GS Amplicon Variant Analyzer. 
 
3.5 ALLELIC IMBALANCE AND MICROSATELLITE INSTABILITY 
The presence of allelic imbalances in selected loci was assessed by making use of 
polymorphic sequence-tagged site (STS) markers. The latter consist of repetitive 
motifs within the genome where the number of repetitions varies across different 
alleles. In an individual heterozygous for a particular STS marker, the distribution of 
the two alleles is normally 1:1. This ratio is altered in the case of allelic imbalances 
such as loss or gain of one of the alleles (Figure 8).  Therefore, by measuring the size 
and ratio of STS markers in a certain position, the presence of allelic imbalances in a 
locus can be detected. To this end, heterozygous STS markers in the vicinity of the 
locus of interest were amplified by PCR using forward primers labeled with 6-
carboxyfluorescein (6-FAM) fluorescent dyes.  
 
 
Figure 8: Example of allelic imbalance. Each 
of the two alleles is represented by a major peak 
surrounded by minor peaks. In the control two 
alleles can be observed whilst in the tumor only 
one is detected.  
 
The amplicons were then loaded onto a capillary DNA analyzer in order to measure 
the fragment’s size and intensity of fluorescence from each of the two alleles. The 
fluorescent signal is proportional to the presence of the individual alleles. The allelic 
distribution of STS markers of tumor samples and paired normal tissues were 
analyzed in order to obtain an interpretable result. An allelic imbalance was called 
when the distribution of alleles between the normal control and the tumor exceeded 
50%. The loci of EXO1, PARP1, MDC1 and RPA1 were assessed for allelic 
imbalances. Analysis of the TP53BP1 locus was attempted as well but proven to be 
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difficult due to a high degree of homozygosity of the STS markers assessed for that 
locus. Two STS markers from each site of the loci were analyzed to ensure the 
accuracy and reproducibility of the result. The markers where selected from the 
UCSC genome browser and the Ensembl genome browser. The primers necessary for 
their amplification were either retrieved from the same databases or designed using 
Primer 3. High-performance liquid chromatography (HPLC) was used for the 
purification of the fluorescently labeled oligonucleotides. The DNA analyzer used 
was a 48-capillary 3730 DNA Analyzer and the generated data was processed with the 
Peak Scanner software by Applied Biosystems.  
The presence of microsatellite instability (MSI) was evaluated in a similar fashion. 
Short tandem repeats (STRs) are repetitive sequences within the genome and can 
serve as markers for MSI. The size of an STR can vary among individuals due to the 
number or repetitions. However, they constitute a genetic fingerprint and the number 
of repetitions remains unaltered under normal circumstances (222). Instability in the 
size of STRs is observed when MMR is impaired (Figure 9) (34). The markers used 
for the detection of MSI were the mononucleotide markers BAT-25 and BAT26, as 
well as the dinucleotide markers S2S123 and D10S197. The marker amplification and 
process by the DNA analyzer was performed in a manner similar to that used for the 
detection of allelic imbalances. However, the analysis consisted of identifying 
changes in the size of the STR markers between the normal control and the tumor 
sample. 
 
 
Figure 9: Example of microsatellite 
instability. Fragment analysis detects an 
additional peak in the tumor sample. This 
indicates instability in the size of the 
microsatellite due to an increase in the number 
of repetitions of the motif. 
 
3.6 NOTCH DUAL LUCIFERASE REPORTER ASSAY 
DTX1 is a negative regulator of the NOTCH signaling pathway. NOTCH1 is a 
transmembrane receptor. Upon engagement by a ligand, the NOTCH1 intracellular 
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domain (NCID1) is translocated to the nucleus where it interacts with the CSL 
transcription factor and drives the expression of its target genes. DTX1 represses the 
expression of those target genes by interacting with NCID1 and inhibiting the 
recruitment of coactivators (223).  
 
 
Figure 10: Notch luciferase reporter assay. Interaction of Notch1 with its ligand leads to the 
liberation of NCID1 into the cytoplasm. NCID1 then translocates to the nucleus where it interacts with 
co-activators and CSL and drives the expression of its target genes. DTX1 acts as a negative regulator 
by binding to NCID1 and inhibiting downstream interactions. In our system, WT DTX1 could bind to 
NCID1 thus inhibiting the expression of firefly luciferase. Some DTX1 mutants (mDTX1) did not 
inhibit the expression of the reporter thus indicating a loss of the ability to bind NCID1. 
 
This interaction between DTX1 and NCID1 was used in order to assess the impact of 
mutations identified on DTX1 by means of a dual luciferase reporter assay (Figure 
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10). cDNA was used as a template for the amplification of the coding region of the 
wild type DTX1 and NCID1. The amplification primers were designed in such a way 
as to confer the ends of the amplicons with restriction sites that allowed their cloning 
into the pcDNA 3.1 mammalian expression vector by Life technologies. Site-directed 
mutagenesis was used for the generation of 14 DTX1 mutants discovered in the 
DLBCL patients by DNA sequencing. The reporter gene, firefly luciferase, was 
cloned into a vector. The expression of firefly luciferase was coupled to the 
transcription element CSL whose activation depends on binding by NCID1. A pRL-
TK plasmid expressing Renilla luciferase served as internal control. The plasmids 
were co-transfected into the U2OS osteosarcoma cell-line using the Turbofect reagent 
by Fermentas. After 48 hours of incubation, the cells were lysed and the firefly 
luciferase levels were measured with the Dual-luciferase reporter assay by Promega 
on a Thermo Scientific Varioskan Flash microplate luminometer. The Renilla 
luciferase levels were also measured and used for normalization. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
 
DNA repair genes are selectively mutated in diffuse large B-cell lymphomas. 
 
This project focused on assessing the role of DNA repair genes in the development of 
lymphomas, especially in relation to the processes of antibody diversification. The 
results showed that 50% of the DLBCLs involved in the study carried mutations in at 
least one of the screened genes. Functional studies also associated defects in specific 
DNA repair mechanisms to unique phenotypes. 
 
4.1.1 Mutations identified in DNA repair genes 
The targeted sequencing of the coding regions of 73 key DNA repair genes across 29 
mature B-cell lymphomas identified a number of somatic, novel germline and rare 
germline (MAF<0.01) mutations. Approximately half of the 442 SNVs identified by 
the SOLiD method passed visual inspection by IGV and 124 resulted in non-
synonymous alterations. Sixty-nine of those were validated by Sanger sequencing. 
This includes all 33 novel and 21 rare germline SNVs as well as 15 of the 21 somatic 
SNVs. The majority of those mutations, including all the somatic mutations, were 
found in the 22 DLBCL tumors despite the comparable sequencing performance in 
the FL and BL tumors. BFAST enabled the discovery of four somatic deletions in four 
different DLBCL tumors. Collectively, the SOLiD sequencing method revealed 73 
non-synonymous mutations in the cohort (Table 3). 
 
4.1.2 Distribution of mutations across DNA repair pathways 
Nineteen somatic and 45 germline mutations were distributed in 22 DLBCL tumors. 
The pathways more frequently affected by mutations were the DDR, MMR, HR and 
NHEJ pathways.  
In the DDR pathway, mutations were found in ATM, MDC1, RAD50, RPA1, TP53, 
and TP53BP1, as well as in two novel mutation targets in DLBCL, CHEK2 and 
PARP1. The EXO1, MLH3, MSH2, MSH3, MSH6, PMS1 and PMS2 MMR factors 
were found to be mutated in our cohort.  The HR factors affected by mutations were 
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BLM, BRCA1, BRCA2, FANCA, FANCG, RAD51B and RAD54B. NHEJ was targeted 
by mutations in the DCLRE1C, PNKP, PRKDC, XRCC5 and XRCC6 genes. 
 
Pathway Gene Somatic Novel germline Rare germline (MAF<0.01) 
DDR ATM p.L1206V; p.Y1215H - p.R629W 
 CHEK2 p.Q336L - p.E528K 
 MDC1 - p.H35L; p.N280D; p.P965L - 
 PARP1 p.K637Sfs*13 p.S776G - 
 RAD50 - p.V400E p.L1125F 
 RPA1 - p.G160R - 
 TP53 p.R273C; p.F134V; p.R273H - p.V31I 
 TP53BP1 - - p.T519A (x2); p.A1714S (x2) 
MMR EXO1 p.K471R - - 
 MLH3 - p.L1111F; p.C40Y p.I988M; p.S946F 
 MSH2 p.S540G; p.L833V p.G820D - 
 MSH3 - p.P657S; p.R1061G (x2) - 
 MSH6 p.K543R p.T563N - 
 PMS1 - p.L369P; p.D397E p.R919C 
 PMS2 - p.M362K p.S128L 
HR BLM - p.S580P p.V765I 
 BRCA1 - - p.Y856H 
 BRCA2 p.V849A; p.M3322I p.S1744I p.C315S; p.I1929V 
 FANCA - p.R1321H; p.T620I - 
 FANCG - p.M431R - 
 RAD51B - p.E346D - 
 RAD54B - p.P55L p.I778V 
NHEJ DCLRE1C p.I543Rfs*12 - - 
 PNKP - p.P112R - 
 PRKDC p.F3418L p.D566N; p.K1984N - 
 XRCC5 p.T283A - - 
 XRCC6 p.I267Kfs*2 - - 
BER LIG3 - p.R343Q - 
 POLB - p.R333Q - 
 UNG - p.E121Q - 
 XRCC1 - - p.A121T 
NER DDB1 p.A9G - p.Y517C 
 ERCC5 - p.D387N - 
 LIG1 - p.T311M - 
Other A20 p.C627Ffs*44 p.P714S - 
 DNTT - p.R335W p.V37I; p.V371I 
Table 3: Somatic, novel germline and rare germline mutations found in DLBCLs by the SOLiD 
sequencing approach. The genes are arranged in pathways; however, some genes belong to more than 
one pathway. LIG1 and LIG3 are involved in BER and NER, and PNKP is involved in BER and 
NHEJ. As a member of the MRN complex, RAD50 participates in all DSB repair pathways. Adapted 
from J Exp Med. 2013 Aug 26;210(9):1729-42. 
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4.1.3 Mutation frequency 
WES data was available for 17 of the 22 DLBCL tumors involved in the study. This 
allowed the comparison of the mutation frequency between DNA repair genes and the 
entire coding genome. The mean frequency of somatic mutations in DNA repair genes 
was 4.21 mutations/Mb versus 3.15 mutations/Mb for the entire coding genome. Of 
note, the mutation frequency in DNA repair genes identified by the SOLiD method in 
the 22 DLBCL samples was 4.16 mutations/Mb which is comparable to the WES 
result. 
Even though DNA repair genes do not appear to be significantly more targeted by 
somatic mutations as compared to the rest of the coding genome, approximately half 
of the DLBCL cohort was affected by somatic mutations in at least one DNA repair 
gene.  
 
4.1.4 Cohort expansion for selected genes 
Seven of the genes harboring mutations identified by the SOLiD method were 
selected for sequencing in expanded cohorts. The Sanger method was used for the 
sequencing of CHEK2, PARP1 and MSH2 in 235, 130 and 94 DLBCLs respectively. 
This included the 22 patients that underwent SOLiD sequencing. The other four 
genes, DDB1, XRCC5, DCLRE1C and MLH3 were sequenced in 48 DLBCL tumors 
using the 454 GS FLX+ Titanium sequencing platform. 
In addition to the two variants identified by the SOLiD method, seventeen tumors that 
did not undergo SOLiD sequencing were found to harbor CHEK2 mutations. These 
were novel mutations and rare germline variants. Among the variants, two were 
splicing mutations, one was a frameshift deletion and one was a premature stop 
codon. The rest were SNVs, most of which were predicted by the SIFT and Polyphen-
2 algorithms to have a damaging effect on the protein function. In summary, 8% of 
the cohort had CHEK2 mutations. Mutations in CHEK2 may contribute to 
carcinogenesis by impairing the signal transmission from DDR sensor proteins to p53. 
Therefore, CHEK2 mutations could compromise cell-cycle checkpoints and the 
induction of apoptosis following DNA damage (224). The sequencing of an additional 
90 DNA samples derived from healthy blood donors did not find any CHEK2 
mutations other than two germline variants that have previously been found by 
genotyping. This further supports the association of CHEK2 variants with the 
development of DLBCL. 
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The Sanger sequencing of PARP1 in the extended cohort identified four additional 
mutations. Those were two rare germline SNVs, one novel premature stop codon and 
one novel SNV. In total, 5% of the cohort was carrying PARP1 mutations. 
MSH2 cohort expansion by the Sanger method revealed a novel SNV and a previously 
reported rare SNV. Overall, MSH2 was mutated in 2% of our cohort. 
The 454 GS FLX+ Titanium platforms identified two novel mutations in DDB1, one 
novel and one rare variant in both MLH3 and XRCC5 and one rare variant in 
DCLRE1C. In summary, the combined sequencing results found DDB1, MLH3, 
XRCC5 and DCLRE1C to be mutated in 6%, 13% 6% and 4% of the tumors 
respectively. 
 
4.1.5 Allelic imbalances 
SOLiD sequencing data also allowed for the comparison of allelic ratios of 
heterozygous germline SNVs between tumors and paired normal controls. This 
approach found imbalances in the loci of EXO1 (6 tumors), PARP1 and RPA1 (3 
tumors each), TP53BP1, ERCC6 and ATR (2 tumors each) and MDC1 (1 tumor). 
Analysis of STS markers in the loci of EXO1, PARP1, MDC1 and RPA1 across 28 
DLBCL tumors and paired normal controls confirmed all but one of the allelic 
imbalances found by the SOLiD method. Moreover, it identified additional cases of 
allelic imbalances in these loci that were not detected through the analysis of the 
SOLiD data. Overall, the RPA1, EXO1, MDC1 and PARP1 loci were affected by 
allelic imbalances in 25%, 21%, 18% and 14% of the tumors respectively.  
An attempt to assess any impact on the expression levels of these genes, found that 
PARP1 is expressed at significantly lower levels in tumors with allelic imbalances in 
the PARP1 locus. This decrease in expression might reflect a loss in copy numbers in 
the locus. This is in conjunction with the observation that high PARP1 activity 
resulting from high levels of DNA damage, is associated with increased cell death 
(225). Therefore, a lower expression of PARP1 might represent a survival mechanism 
in these tumors. The expression levels of RPA1, EXO1 and MDC1 did not appear 
altered by the presence of allelic imbalance in their loci. 
 
4.1.6 Microsatellite instability and mutational load 
MSI analysis of four STR markers was performed in order to detect genetic instability 
induced by the presence of MMR defects. The results showed MSI in four of the 28 
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tumors analyzed. Interestingly, all four tumors harbored mutations in at least one 
MMR gene. In addition, in one sample with an MSH2 mutation from which a paired 
normal control was not available, MSI analysis was performed using Promega’s MSI 
analysis system employing five mononucleotide markers. MSI was detected in this 
sample as well bringing the total number of MMR-mutated samples affected by MSI 
to five. Mutations in the MMR pathway have previously been associated with MSI in 
other malignancies, but never before in DLBCL (34).  
 
 
Figure 11: Increased mutation load in tumors with MSI/MMR mutations. Mutations in the MMR 
pathway were associated with MSI. The same tumors exhibited a higher mutational load as compared 
with the rest of the cohort, especially in the case of insertions and deletions. * P<0.05. 
 
Moreover, MMR deficiencies have been associated with higher mutation loads in 
other human malignancies such as gastric carcinoma (226). WES data from the five 
MSI samples, 14 microsatellite stable (MSS) samples and their paired controls was 
used in order to investigate for associations between MMR defects and mutational 
load or mutation signatures. The MSI tumors were characterized by a heavier 
mutational load as compared to the MSS tumors even though statistical significance 
was marginally not attained (Mann-Whitney P=0.05). Interestingly however, the 
presence of indels was significantly higher in the MSI tumors (P=0.02) and three out 
of the four deletions identified by the SOLiD method were found in MMR-deficient 
tumors displaying MSI (Figure 11).  
Furthermore, the MMR-mutated MSI tumors associated with a particular mutational 
signature as C:G>A:T transversions were significantly more common in these tumors. 
In B-cells, MMR is involved in the processing of mismatches induced by the 
mutagenic activity of AID during CSR and SHM and protects the genome from off-
target AID activity (34, 52, 227-230). Therefore, the enrichment in C:G>A:T 
 44 
transversions in these tumors might reflect a compromised surveillance of the AID 
activity due to MMR deficiencies. Accordingly, the presence of G:C>A:T 
transversions has previously been associated with MMR-deficiencies in mice, further 
supporting a role for MMR-deficiency in the etiology of DLBCL (231). 
 
4.1.7 NHEJ defects and chromosomal translocations 
Tissue sections were available from 13 DLBCL samples including three of the four 
tumors presented with NHEJ defects. Fluorescence in situ hybridization (FISH) was 
used in order to investigate whether these mutations associate with breakpoints in the 
locus of IGH. Dual-color break-apart probes were used to assess the status of the IGH 
and BCL6 loci that are often found rearranged in DLBCL. The results found two 
samples with breaks in the IGH locus, both of which were harboring NHEJ mutations 
(XRCC5 and DCLRE1C). None of the tumors with wild type NHEJ genes were 
affected by breaks in the IGH locus. This finding indicates that NHEJ defects might 
be involved in the formation of translocations between the IGH locus and proto-
oncogenes in DLBCL. Of note, breaks in the BCL6 locus were also observed in the 
two samples with IGH breaks; however, there was no further evidence supporting that 
the two loci were indeed juxtaposed to each other. 
 
 
4.2 PAPER II 
 
Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas 
derived from Chinese patients. 
 
In this paper, a WES approach was used to identify genes targeted by mutations in 
DLBCL and describe the frequency at which they are affected. The results revealed a 
number of novel and driver mutation targets for Chinese patients and underscored the 
genetic heterogeneity of DLBCL. Moreover, the functional implications of mutations 
in two of the most interesting gene targets, DTX1 and LYN, were addressed 
experimentally. 
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4.2.1 Whole exome sequencing results 
The coding genome of 31 Chinese DLBCL tumors and their normal blood controls 
were analyzed by WES. All variants reported below passed visual inspection by IGV. 
The number of somatic non-synonymous mutations identified in each tumor varied 
from 8 to 183 (median=54). In agreement with the findings of Paper I, the five tumors 
with somatic mutations in MMR genes presented heavier mutational loads than the 
remaining 26 tumors. 
 
Gene This study Morin et al. 
(2011) 
Pasqualucci et al. 
(2011) 
Lohr et al. 
(2012) 
Zhang et al. 
(2013) 
CD70 23% 7% - 10% - 
B2M 23% 8% 13% 10% 4% 
MYD88 19% 13% 8% 12% 15% 
TMSB4X 19% - - - - 
TP53 16% 12% 17% 25% 5% 
BTG2 16% 13% - 2% - 
UBE2A 13% - 17% 6% - 
SLITRK3 13% - - - - 
IGLL5 13% - - - - 
DCDC5 13% - - - - 
DTX1 13% - - 6% 4% 
LYN 10% - - - - 
CD79B 10% 8% 12% 16% 8% 
A20 10% 3% 15% 2% 10% 
MLL2 6% 22% 23% 29% - 
BCL2 3% 28% 9% 23% 4% 
EZH2 3% 22% 6% 14% 1% 
CARD11 3% 10% 10% 20% 11% 
MEF2B - 15% 8% 18% 3% 
Table 4: Gene mutation frequencies across different DLBCL NGS studies. Adapted from 
Blood. 2014 Oct 16;124(16):2544-53. 
 
Non-synonymous mutations in at least 4 of the 31 tumors (~13%) were identified in 
28 genes. These genes included common and previously described mutational targets 
in DLBCL, as well as the novel recurrently mutated genes TMSB4X, DCDC5, IGLL5 
and SLITRK3. In addition, a number of known targets in DLBCL were mutated at 
higher frequencies (CD70, B2M, BTG2 and DTX1) or lower frequencies (BCL2, 
EZH2, MEF2B and MLL2) in our cohort as compared to similar studies focused on 
Western cohorts (Table 4) (132-134, 207). Differences in the mutation frequencies 
between our results and those of previous studies might reflect the exposure to 
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different environmental mutagens or a different germline background. LYN was found 
mutated in 3 of the 31 samples (10%) and was an additional target of interest due to its 
involvement in the BCR/NF-κB pathway’s regulation. The BCR/NF-κB pathway is 
often affected by mutations in MYD88, CARD11 and CD79B that lead to its 
constitutive activation in DLBCL. LYN however has not before been described as 
recurrently mutated in DLBCL. 
The Molecular Signatures Database allowed for the assignment of genes carrying non-
synonymous somatic mutations into canonical pathways. The most frequently affected 
processes included antigen processing and immune recognition, apoptosis, the 
BCR/NFkB pathway, chemokine and toll-like receptors, JAK/STAT signaling, cell 
cycle control, and Notch signaling.  
 
4.2.2 Cohort expansion 
Sanger sequencing was used for the sequencing of the coding regions of selected 
mutation targets in an expanded cohort of DLBCLs. TMSB4X, CD70, B2M, DTX1, 
LYN and UBE2A were analyzed across 136 Chinese DLBCL tumors including the 31 
that underwent WES. A20 and TP53 were analyzed in 91 samples. The cohort 
expansion found the CD70, TMSB4X, B2M, A20, DTX1, UBE2A, TP53 and LYN to be 
mutated in 22%, 16%, 13%, 14%, 12%, 10%, 9% and 8% of the cohort respectively.  
 
4.2.3 CD70 mutations 
CD70 is a surface signaling molecule involved in the regulation of immunity by 
binding to CD27, its receptor on T-cells (193). In our cohort, CD70 was the most 
frequently mutated gene. Remarkably, approximately 50% of the CD70 mutations 
identified here resulted in premature stop codons or were located on splice sites, 
suggesting a deleterious effect for those variants. Moreover, WGS data from 10 
samples identified copy number losses in the CD70 locus in three samples. Taken 
together, this data suggests that CD70 mutations contribute to the lymphomagenesis 
of DLBCL by disrupting anti-tumor T-cell activity. 
 
4.2.4 DTX1 mutations 
DTX1 acts as negative regulator of the Notch signaling pathway (223). In a subset of 
DLBCL, Notch signaling is activated by gain-of-function mutations in NOTCH1 and 
NOTCH2 (232). However, in our WES sequencing effort only one NOTCH1 and two 
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NOTCH2 mutations were identified. Screening of mutational hotspots of NOTCH1 
and NOTCH2 in 91 DLBCLs found them to be mutated in 6% and 7% of the cohort 
respectively. DTX1 was mutated in 12% of the tumors and was therefore the most 
frequently targeted component of the Notch signaling pathway in our cohort. 
Interestingly, DTX1 and NOTCH1 or NOTCH2 mutations were in general not found 
together in the same patients (Table 5). This further suggests that DTX1 mutations are 
an additional mechanism of Notch signaling activation in DLBCL and highlights the 
importance of the pathway in lymphomagenesis. Screening for DTX1 mutations in a 
cohort of Swedish DLBCLs found alterations in 3 out of the 35 tumors (9%), a result 
comparable to that of the Chinese cohort. 
 
Gene Sample Mutations 
DTX1 DL19 p.G58D  
 DL27 p.M10L; p.F82L 
 DL29 p.H34R; p.A56T; p.G58D 
 DL30 p.F17Y 
 DL34 p.G7D; p.W30* 
 DL42 p.E33D 
 DL44 p.P11S; p.W30*; p.[T43_C45delinsS]; p.L69Q 
 DL49 p.P18L; p.W30C; p.W30*; p.H34N; p.H34Y; p.Q77E 
 DL52 p.P11fs*2 
 DL64 p.W28*; p.I73V; p.I74fs*112; + splice site mutation  
 DL72 p.G58D 
 DL95 p.Q68H; p.Q81L 
 DL103 p.P39R 
 DL119 p.W30* 
 DL121 p.S78C 
 DL137 p.E54K 
NOTCH1 DL40 p.H2241L 
 DL41 p.Q2501* 
 DL69 p.N2528K 
 DL80 p.E2515* 
 DL87 p.L1703Q 
NOTCH2 DL14 p.Q2409* 
 DL20 p.E2420K 
 DL29 p.Q2285* 
 DL62 p.D2163N 
 DL93 p.R2400* 
 DL98 p.P2157T 
Table 5: DTX1, NOTCH1 and NOTCH2 non-synonymous mutations. Mutations in DTX1 and 
NOTCH1 or NOTCH2 are generally mutually exclusive, with the sole exception of sample DL29. 
Adapted from Blood. 2014 Oct 16;124(16):2544-53. 
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All of the 43 DTX1 mutations identified in the Chinese cohort were located in exon 1. 
Interestingly, many of them were G:C>A:T transversions found within WRC/GYW 
motifs which suggests aberrant AID targeting. However, FISH analysis in 35 tumors 
with DTX1 mutations revealed no breaks in the locus of DTX1 that would indicate 
translocations. 
The impact of 14 of the mutants was assessed by means of a dual luciferase assay as 
described in the methods section. Four of the mutants demonstrated a significantly 
decreased inhibition of expression of the luciferase reporter gene, suggesting a 
functional consequence for those mutations. Importantly, those four mutations were 
present in 40% of the samples in which non-synonymous DTX1 alterations were 
identified. 
 
4.2.5 LYN mutations 
LYN acts as a negative regulator of BCR signaling. It is a tyrosine kinase implicated in 
signal transduction through the phosphorylation of factors associated with the BCR 
complex and CD22 (233). Interestingly, studies in mice have shown an association 
between LYN deficiencies and autoimmune and myeloproliferative diseases (234, 
235). Therefore, deleterious LYN mutations might interfere with the downregulation 
of BCR signaling and contribute to the constitutive activation of the NF-κB pathway 
(Figure 12).  
The mutations identified in our cohort were located mostly in the protein’s kinase 
domain which is responsible for the phosphorylation of downstream factors (234). 
Furthermore, approximately one third of the non-synonymous mutations led to 
premature stop-codons and truncated peptides.  
To analyze the effect of 7 of these mutations at the protein level, U2OS cells were 
transfected with a mammalian expression vector carrying the wild type LYN or one of 
the 7 mutations. The cells were cultured for 48 hours before being analyzed by 
Western blot. As expected, no protein was detected in the cells transfected with LYN 
mutants harboring premature stop-codon mutations. In addition, reduction in the 
protein levels was observed in one of the missense mutants indicating that this 
particular mutation might lead to a less stable peptide. Further functional 
characterization of the missense mutations in the kinase domain could elucidate their 
impact on LYN’s function as a regulator of BCR signaling. 
 
 
  49 
Of note, LYN was also sequenced in 96 Swedish DLBCLs and the mutation rate in 
this cohort was only 2%, indicating a population bias. 
 
 
Figure 12: BCR/NF-κB signaling. Deleterious mutations in CD79B, CARD11, MYD88 and A20 are 
recurrent in DLBCL. LYN mutations could represent an additional mechanism contributing to the 
constitutive activation of the NF-κB pathway in DLBCL. Interestingly, as LYN is found upstream of 
BTK, targeting with BTK inhibitors could be envisioned as a treatment modality for these patients. 
 
 
4.3 PAPER III 
 
Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. 
 
This project investigated the role of cytogenetic alterations as mechanisms of PD-1-
ligand upregulation in DLBCL. Moreover, it described the distribution of those 
alterations across the disease subtypes and their impact on survival. Finally, it 
discussed how this could influence the treatment of DLBCL by therapies targeting the 
PD-1 – PD-L1/PD-L2 pathway. 
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4.3.1 Cytogenetic alterations, disease subtype and patient survival 
The genes coding for the PD-1 ligands, PD-L1 and PD-L2, are located adjacent to 
each other on Chromosome 9-p.1. FISH probes targeting Chromosome 9-p.1 were 
used in order to assess the cytogenetic status of the locus across a cohort of 170 
DLBCLs. The cohort was composed of 80 Chinese, 64 Swedish and 26 American 
patients. Twenty-two samples were presented with Chromosome 9-p.1 copy gains, six 
with locus breaks and two with locus amplification representing 13%, 4% and 1% of 
the cohort respectively. Locus amplification was defined as the presence of at least 
five copies of the locus per cell. Intriguingly, one of the samples presented with a 
break in the PD-L1/PD-L2 locus was already known to be deficient for the NHEJ 
gene DCLRE1C and harbored breaks in the IGH locus. This was known from our 
previous work presented in Paper I. Collectively this information suggests that the 
translocation partner of IGH in this sample may be the PD-L1/PD-L2 locus. 
The molecular subtype of the disease was made known by the Han’s algorithm for 
122 of the samples. Forty-nine samples (40%) belonged to the GCB subtype whilst 73 
(60%) belonged to the non-GCB subtype. The results showed that cytogenetic 
alterations affecting the PD-L1/PD-L2 locus were more frequent in the non-GCB 
samples. Specifically, only 4 of the 49 GCB samples were found to have alterations in 
the locus vs 19 of the non-GCB samples. It is notable that all the locus breaks and 
amplifications were exclusively found in samples belonging to the non-GCB subtype. 
Data from previous studies suggests that PD-L1 is expressed mostly by non-GCB 
DLBCLs (88). This prompts speculation that the higher expression of PD-L1 in non-
GCB DLBCL might, in part, be due to cytogenetic alterations.  
A trend towards decreased survival was observed in patients harboring alterations in 
the PD-L1/PD-L2 locus as compared with the remaining patients. More importantly 
however, the presence of breaks in the PD-L1/PD-L2 locus showed a strong 
association with a rapid disease progression and a sharp decrease in patient survival. 
Statistical significance was observed even when the survival analysis was restricted to 
the non-GCB subtype. Therefore this decrease in survival is independent of the 
disease subtype.  
 
4.3.2 Identification of translocation partners by WGS 
To confirm and further characterize the locus breaks and amplifications, WGS was 
performed on five of the affected tumors from which DNA was available. Four 
tumors harbored locus breaks and one was presented with locus amplification. In three 
of the four samples with locus breaks, SV analysis revealed the exact location of the 
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breakpoints and identified the translocation partners. One tumor with a locus break 
was left unresolved probably due to DNA material degradation. The PD-L1/PD-L2 
locus was juxtaposed to the Sμ region of the IGH locus in two of the samples 
including the one with a DCLRE1C deficiency. Of note, the translocation in this 
particular sample was also demonstrated by a 4-color FISH experiment (Figure 13). In 
addition, breaks in the PD-L1/PD-L2 and IGH loci were found in the unresolved case 
suggesting that the two loci may be juxtaposed in this sample as well. This data shows 
that the PD-L1/PD-L2 locus is a recurrent IGH translocation partner in DLBCL. In the 
4th sample, the identified translocation partner was PIM1, a gene recurrently mutated 
in DLBCL and an aberrant SHM target (236) (Figure 14). Finally, copy number 
variation analysis confirmed the amplification identified by FISH.  
 
 
Figure 13: FISH analysis utilizing 4 colors. The rearrangement between the PD-L1/PD-L2 and IGH 
loci is demonstrated here. The probes and the fluorophore’s color used to label each probe are shown 
above the illustration of the loci. 
 
4.3.3 PD-L1 and PD-L2 RNA expression analysis 
RNA sequencing was available for 18 of the samples that underwent cytogenetic 
analysis by FISH. The median expression levels of PD-L1 were 9.4 FPKM. However, 
in two of the samples with suspected translocations between the IGH and PD-L1/PD-
L2 loci, the expression levels exceeded 40 FPKM suggesting that translocation to the 
IGH locus may lead to an upregulation or PD-L1 expression. Collectively, a trend 
toward higher expression of PD-L1 was observed in the samples harboring 
cytogenetic alterations, although, the results fell short of statistical significance 
probably due to the limited number of samples available. qPCR was performed in a 
larger number of samples (n=29) and found the expression of PD-L1 to be 
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significantly higher in samples with alterations in the locus. Of note, no association 
was found between cytogenetic alteration and the expression levels of PD-L2. 
 
Figure 14: Circus plot showing the PD-L1/PD-L2 translocation partners.  The plot shows the 
locations of the concerned loci within the genome. 
 
4.3.4 PD-L1 protein expression 
PD-L1 immunostaining was performed on 167 of the samples and found 43 of them 
(26%) to be positive for PD-L1 protein expression. A strong association to 
cytogenetic alterations was found as 56% of the samples with copy gains, locus breaks 
or amplifications were expressing PD-L1 versus only 20% in the remaining samples. 
Notably, all samples with breaks/translocations and amplifications in the PD-L1/PD-
L2 locus were found to be positive for PD-L1 protein expression. This data provides 
further evidence that cytogenetic alterations, especially translocations and 
amplifications, constitute mechanisms of PD-L1 overexpression in DLBCL. 
Moreover, along with the decreased survival observed in patients with translocations, 
it suggests that a number of patients with aggressive DLBCL disease could benefit 
from therapies targeting the PD-1 – PD-L1/PD-L2 axis. 
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4.3.5 HLA class I expression 
HLA class I is essential for antigenic presentation and recognition by cytotoxic CD8+ 
T-cells. In most cancers, loss of HLA class I expression masks tumors from cytotoxic 
T-cells regardless of the expression status of PD-L1. The expression of the HLA class 
I complex was assessed in 90 tumors from the cohort and 39% were found to be 
negative. Contrary to expectation, almost all of the samples with breaks or 
amplifications in the PD-L1/PD-L2 locus were negative for HLA class I. This could 
perhaps be attributed to the particular physiological function of B-cells. As 
professional APCs, B-cells express HLA class II which presents antigenic 
determinants to CD4+ helper T-cells. Therefore, overexpression of PD-L1 in DLBCL, 
even in the absence of HLA class I expression, might confer malignant cells with 
further protection from immunity via an HLA class II dependent mechanism (Figure 
15). 
 
 
Figure 15: Immune evasion. Loss of HLA I suffice for immune escape from CD8+ T-cells. However, 
as DLBCLs express HLA class II, expression of PD-L1 can shield them from CD4+ T-cell-mediated 
immune responses. 
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5 CONCLUDING REMARKS AND PERSPECTIVES 
This thesis aimed to characterize the genome of DLBCL and describe novel mutation 
targets and structural alterations that contribute to the lymphomagenesis of DLBCL. 
Furthermore, this thesis attempted to explore how the knowledge generated by 
sequencing can contribute to new approaches in the treatment of DLBCL. 
 
The key findings of this work are: 
- Genes participating in DNA repair and antibody diversification are commonly 
affected by somatic and germline mutations in DLBCLs. In summary, 50% of the 
tumors in our cohort carry somatically acquired mutations in at least one DNA repair 
gene. Moreover, mutations in certain pathways can be associated with specific 
phenotypes. More specifically, MMR deficiencies translate into MSI and an increased 
mutational load, and NHEJ defects may predispose B-cells to chromosomal 
translocations involving the IGH locus due to an improper resolution of DSB. 
- DLBCL is a heterogeneous disease characterized by a diverse mutational landscape 
and the incidence of mutations in certain genes varies across populations. A notable 
example is CD70 which was found to be mutated at a much higher frequency in our 
cohort of Chinese patients, as compared to previous studies focusing on DLBCLs 
from Western populations.  
- DTX1 is recurrently targeted by mutations in DLBCLs and is the most commonly 
mutated member of the Notch pathway in Chinese DLBCLs. These mutations might 
be the result of illicit AID activity as they are mostly G:C>A:T transversions 
concentrated in WRC/GYW motifs. Importantly, a number of these mutations appear 
to have a deleterious effect on the function of DTX1 as a negative regulator of Notch. 
- LYN is a novel mutational target in DLBCL. Most of the mutations identified in our 
cohort are located in the protein’s kinase domain, thereby suggesting a deleterious 
effect on protein function. Moreover, they often lead to premature stop-codons. 
Therefore, LYN deficiencies might represent an additional mechanism for constitutive 
activation of the BCR/NF-κB pathway. 
- Cytogenetic alterations involving the PD-L1/PD-L2 locus, especially translocations, 
constitute an intrinsic mechanism for PD-L1 expression in DLBCLs. These structural 
variations were mostly found in the more aggressive non-GCB subtype. A sharp 
decrease in survival was observed in patients with PD-L1/PD-L2 translocations and 
this was independent from the disease subtype. Finally, the PD-L1/PD-L2 locus is 
described as a novel and recurrent IGH translocation partner in DLBCL. 
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Collectively, the results of this thesis show that a considerable proportion of the 
DLBCL patients are affected by deficiencies in pathways that are potentially 
targetable by therapies that are currently available or in development (Table 6). 
Therefore, a careful evaluation of patients and molecular characterization of each case 
can optimize therapy. This, in conjunction with the new developments in 
pharmacogenetics, could greatly improve disease outcomes. 
 
Molecule class Target Findings in the study cohort 
PD-1/PD-L1 therapeutic antibodies PD-1 – PD-L1 pathway PD-L1 overexpression 
CD27 agonists CD70 – CD27 pathway CD70 mutations & copy losses 
Notch signaling factor inhibitors Notch signaling DTX1 mutations 
BTK inhibitors BCR/NF-κB pathway LYN mutations 
PARP1 inhibitors HR deficiencies Mutations in HR factors 
NEDD8 activation inhibitors Ubiquitin-proteasome system UBE2A mutations 
EGFR/HER2 blockade EGFR tyrosine kinases BTG2 mutations 
Table 6: Defects identified in DLBCL tumors and potentially appropriate therapies that could benefit 
patients. 
 
The expression of PD-L1 primarily by the non-GCB DLBCLs indicates that patients 
could be stratified and therapies targeting PD-1 or PD-L1 could be directed to patients 
with aggressive disease. Recently, a number of biomarkers that predict the response 
rate to therapies targeting the PD-1 – PD-L1 interaction have been identified. 
Expression of PD-L1 by the tumor cells or the tumor microenvironment has been 
associated to better responses. Intriguingly, however, even PD-L1-negative tumors 
have been found to respond to anti-PD-1 or anti-PD-L1 blockade to some extent (77, 
237). In addition, better responses have been observed in tumors infiltrated by CD8+ 
T-lymphocytes (238).  
Interestingly, one of the DLBCLs enrolled in this study harbored a PD-L1 – IGH 
translocation and was found to be mutated for the NHEJ factor DCLRE1C and the 
MMR factor MSH2. MMR is involved in the processing of AID-induced mismatches 
in CSR, and NHEJ resolves the ensuing DSB (17, 227). It is therefore possible that the 
PD-L1 – IGH translocation in this sample may be the result of this combination of 
NHEJ and MMR mutations. Moreover, this is further supported by the fact that the 
breakpoint within the PD-L1 gene is located within a WRC/GYW motif. In addition, 
this tumor, along with others harboring MMR deficiencies was presented with a 
heavier mutational load. Literature suggests that a higher number of mutations leads to 
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a rise in the number of neo-antigens rendering tumors more immunogenic (75). 
Studies have also suggested that as a consequence, tumors are more likely to respond 
to immunotherapy (239, 240). Taken together, this indicates that MMR mutations 
could constitute a biomarker for the selection of patients likely to respond to therapies 
targeting the PD-1 – PD-L1 axis.    
The high prevalence of CD70 mutations in our cohort indicates that immunotherapies 
targeting the CD70 – CD27 axis may also benefit DLBCL patients. Loss of CD70 
might confer the tumor with an immune-suppressing activity by impeding CD27-
mediated T-cell activation. Therefore, the use of CD27-activating antibodies may 
restore T-cell function in CD70 deficient patients (194). 
LYN, a member of the BCR signaling pathway was found to be mutated in a 
considerable subset of the enrolled patients. The consequences of LYN mutations 
should be carefully investigated as they could contribute to the chronic activation of 
the NF-κB pathway. Follow-up studies could investigate the impact of LYN mutations 
on its kinase activity and how LYN deficiencies affect the expression of the NF-κB 
pathway factors. Moreover, the use of inhibitors of downstream effector molecules 
such as BTK could be envisioned for those patients. 
DTX1 was mutated in 12% of our cohort. Together with other studies reporting 
mutations in NOTCH1 and NOTCH2, they support that therapies targeting the Notch 
signaling pathway could also prove beneficial for DLBCL patients. 
Additionally, PARP1 was found mutated or expressed at lower levels in a subset of 
our cohort. Targeting of PARP1 in tumors deficient for HR leads to synthetic lethality 
and cell death. However, as a number of DLBCLs are already deficient for PARP1, it 
is likely that they will be insensitive to such therapies and patients should therefore be 
carefully evaluated prior to treatment. 
 
The considerable efforts that have been made in recent years to characterize the 
genome of DLBCL have identified the most commonly mutated genes. The work 
conducted for this thesis reported a number of previously unknown mutational targets 
and underlined the heterogeneous genetic landscape of DLBCL. However, the 
collective results from this and previous studies prompt further investigation in order 
to achieve a comprehensive understanding of the DLBCL genome.  
Down-sampling analysis of available data suggested that the genome of 2000 tumors 
must be sequenced in order to reach gene discovery saturation in DLBCL. It is 
estimated that this will identify 90% of the genes that are mutated in as low as 2% of 
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the patients (241). This is instrumental to the transition towards personalized medicine 
and a targeted therapy approach for the treatment of cancer. A profound knowledge of 
the disease landscape can guide the efforts for the development of novel drug 
molecules. Furthermore, in conjunction with patient screening upon diagnosis, it can 
provide individual patients with a treatment tailored to the genetic alterations 
characterizing their disease. 
Our group is currently working towards this goal in collaboration with the Beijing 
Genomics Institute in order to develop a patient screening chip. The purpose of this 
effort is to provide a standardized and rapid diagnostic tool at a much lower cost than 
the currently available sequencing methods. It will enable the screening of newly-
diagnosed or relapsed patients for defects in common mutational targets and assess the 
sensitivity of their disease to currently available treatments. Therefore, it will enable a 
more careful evaluation of each patient, provide a more accurate prediction of the 
disease outcome and direct a personalized selection of treatment. Patients could thus 
benefit from targeted therapies that are currently difficult to implement.  
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